Neurocrine Biosciences, Inc. (NBIX) Monday said the Food and Drug Administration or FDA has granted priority reviews for the company's two New Drug Applications for crinecerfont for the treatment of children, adolescents and adults with congenital adrenal hyperplasia.
Congenital adrenal hyperplasia (CAH) is a group of genetic conditions that affect the adrenal glands. It impedes a child's normal growth and development.
The NDA's included a capsule formulation as well as an oral solution formulation of crinecerfont, for which decisions are expected on December 29 and December 30, 2024, respectively.
If approved, crinecerfont would be the first new treatment option for CAH in 70 years.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.